Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol.
暂无分享,去创建一个
[1] W. L. Nelson,et al. Metabolic kinetics of pseudoracemic propranolol in human liver microsomes. Enantioselectivity and quinidine inhibition. , 1994, Drug metabolism and disposition: the biological fate of chemicals.
[2] E. Skjelbo,et al. Inhibitors of imipramine metabolism by human liver microsomes. , 1992, British journal of clinical pharmacology.
[3] K. Chiba,et al. The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. , 1994, British journal of clinical pharmacology.
[4] R. Obach. The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[5] J. Strong,et al. Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: implications for clinical correlation. , 1997, The Journal of pharmacology and experimental therapeutics.
[6] C. D. Francesco,et al. Membrane lipids as intracellular binders of chlorpromazine and related drugs. , 1977, Chemico-biological interactions.
[7] A. Guillouzo,et al. Report on the international workshop on the use of human in vitro liver preparations to study drug metabolism in drug development. Held at Utrecht, The Netherlands, 6-8 September 1994. , 1995 .
[8] Grant R. Wilkinson,et al. A physiological approach to hepatic drug clearance , 1975 .
[9] C. B. Kristensen. Imipramine serum protein binding in healthy subjects , 1983, Clinical pharmacology and therapeutics.
[10] P. McNamara,et al. Age and propranolol stereoselective disposition in humans , 1992, Clinical pharmacology and therapeutics.
[11] T Ishizaki,et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.
[12] G R Wilkinson,et al. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. , 1977, The Journal of pharmacology and experimental therapeutics.
[13] J. Lin,et al. Kinetic studies on the deethylation of ethoxybenzamide. A comparative study with isolated hepatocytes and liver microsomes of rat. , 1980, Biochemical pharmacology.
[14] J. Houston,et al. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. , 1995, The Journal of pharmacology and experimental therapeutics.
[15] A. Breckenridge,et al. Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. , 1974, The Journal of clinical investigation.
[16] F. Sallee,et al. Clinical Pharmacokinetics of Imipramine and Desipramine , 1990, Clinical pharmacokinetics.
[17] A. Glassman,et al. Plasma binding of imipramine and clinical outcome. , 1973, The American journal of psychiatry.
[18] M. Chiba,et al. Pharmacokinetic correlation between in vitro hepatic microsomal enzyme kinetics and in vivo metabolism of imipramine and desipramine in rats. , 1990, Journal of pharmaceutical sciences.
[19] A. Breckenridge,et al. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man , 1974, Clinical pharmacology and therapeutics.
[20] M. Bickel,et al. Binding of basic and acidic drugs to rat tissue subcellular fractions. , 1974, Chemico-biological interactions.
[21] M. Gibaldi,et al. Metabolic enantiomeric interactions: the inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin. , 1991, Chirality.
[22] M. Gibaldi,et al. Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. , 1989, Drug metabolism and disposition: the biological fate of chemicals.
[23] G. Tucker,et al. Propranolol oxidation by human liver microsomes--the use of cumene hydroperoxide to probe isoenzyme specificity and regio- and stereoselectivity. , 1990, British journal of clinical pharmacology.
[24] R. Branch,et al. Biological determinants of propranolol disposition in man , 1978, Clinical pharmacology and therapeutics.
[25] E. Chan,et al. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. , 1994, British journal of clinical pharmacology.
[26] T. Walle,et al. Quantitative account of propranolol metabolism in urine of normal man. , 1985, Drug metabolism and disposition: the biological fate of chemicals.
[27] T. Walle,et al. Partial metabolic clearances as determinants of the oral bioavailability of propranolol. , 1986, British journal of clinical pharmacology.
[28] T. Moreland,et al. Studies on a ketone reductase in human and rat liver and kidney soluble fraction using warfarin as a substrate. , 1975, Biochemical pharmacology.
[29] J B Houston,et al. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.
[30] D. Morgan,et al. (S)-4'-hydroxypropranolol causes product inhibition and dose-dependent bioavailability of propranolol enantiomers in the isolated perfused rat liver and in rat liver microsomes. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.
[31] P. Beaune,et al. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. , 1993, Molecular pharmacology.
[32] I Skånberg,et al. In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. , 2009, Acta pharmacologica et toxicologica.